Alekshun Todd, Garrett Chris
Medical Oncology/Hematology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612-9797, USA.
Cancer Control. 2005 Apr;12(2):105-10. doi: 10.1177/107327480501200205.
In solid organ malignancies, no tumor type has seen a greater impact from the development of novel targeted therapies in 2004 than metastatic colorectal cancer.
We review the current progress to date with the use of monoclonal antibodies in colorectal cancer and look at newer therapies under investigation.
Two monoclonal antibodies received Food and Drug Administration approval in early 2004, both for the indication of advanced, metastatic colorectal cancer. A large, randomized, placebo-controlled study demonstrated that the addition of a monoclonal antibody to vascular endothelial growth factor, bevacizumab, led to a statistically significant improvement in overall survival, with tolerable additional toxicity. Chimeric monoclonal antibody therapy directed at the epidermal growth factor receptor was associated with radiographic responses in a significant minority of patients with irinotecan-refractory colon cancer in a randomized phase II study of patients with irinotecan-refractory disease.
These dramatic successes have led to further clinical studies of targeted therapy in colorectal cancer, making it one of the most promising areas of cancer research.
在实体器官恶性肿瘤中，2004年新型靶向治疗的发展对任何肿瘤类型的影响都不及转移性结直肠癌。
我们回顾了目前在结直肠癌中使用单克隆抗体的进展，并审视正在研究的更新型治疗方法。
2004年初，两种单克隆抗体获得了美国食品药品监督管理局的批准，均用于晚期转移性结直肠癌的治疗。一项大型随机安慰剂对照研究表明，添加针对血管内皮生长因子的单克隆抗体贝伐单抗可使总生存期有统计学意义的显著改善，且额外毒性可耐受。在一项针对伊立替康难治性疾病患者的随机II期研究中，针对表皮生长因子受体的嵌合单克隆抗体疗法在少数伊立替康难治性结肠癌患者中产生了影像学反应。
这些显著成功促使结直肠癌靶向治疗的进一步临床研究，使其成为癌症研究中最有前景的领域之一。
